Boston Scientific (NYSE:BSX), a longtime vocal opponent of the medical device tax, has argued that the 2.3% tax would kill jobs in the industry. However, a report from the Boston Business Journal shows that the company’s U.S. headcount has remained constant over the past year.
In its recent annual filing, the Marlboro-based firm said it ended the year with 27,000 employees and that 14,000 of them are based outside of the U.S. That figure is up from a year earlier, when the company reported a global headcount of 25,000 with 12,000 of them out of the country.
